Abstract
The acute and chronic effects on blood coagulation and fibrinolysis of a new molecular weight dermatan sulphate (Desmin 370) have been investigated in a double blind, placebo-controlled cross over study in 12 healthy volunteers. The compound (100 and 200 mg) was injected IM and the expected heparin cofactor II potentiating effect, reflecting dermatan sulphate activity, peaked after 2h and was still detectable after 9 h. Surprisingly for this type of compound, a substantial increase in anti-Xa activity also appeared and lasted up to 12 h in the absence of a significant change in aPTT. The bovine-thrombin time was not changed, while human-thrombin times were slightly, albeit non-significantly, prolonged. The activity of t-PA was increased 6h after the higher dose, but the overall pattern of fibrinolytic activities did not suggest any important change after drug treatment in comparison to placebo. No residual or cumulative effect on any of the investigated parameters was detectable 24h after the injection on the 4th and 8th days during repeated daily administration. Parallel in vitro and in vivo investigations showed that the unexpected anti-Xa effect was not attributable to contamination by traces of low molecular weight heparin. Desmin 370, a low molecular weight dermatan sulphate that potentiates heparin cofactor II and also inhibits Factor Xa, deserves clinical evaluation as an antithrombotic agent.
Similar content being viewed by others
References
Tollefsen DM, Petska CA, Monafo WJ (1983) Activation of heparin cofactor II by dermatan sulfate. J Biol Chem 258: 6713–6716
Ofosu FA, Modi GJ, Smith LM, Cerskus AL, Hirsh J (1984) Heparan sulfate and dermatan sulfate inhibit the generation of thrombin activity in plasma by complementary pathways. Blood 64: 727–747
Abbadini M, Zhu GJ, Maggi A, Pangrazzi J, Donati MB, Mussoni L (1987) Dermatan sulfate induces plasminogen activator release in the perfused rat hindquarter. Blood 70: 1858–1860
Dol F, Houin G, Rostin M, Montastruc JL, Dupouy D, Gianese F, Sie P, Boneu B (1989) Pharmacodynamics and pharmacokinetics of dermatan sulfate in humans. Blood 74: 1577–1582
Dol F, Petitou M, Lormeau JC, Choay J, Caranobe C, Sie P, Saivin S, Houin G, Boneu B (1990) Pharmacologic properties of a low molecular weight dermatan sulfate: comparison with unfractionated dermatan sulfate. J Lab Clin Med 115: 43–51
Saivin S, Dol F, Caranobe C, Petitou M, Lormeau JC, Sie P, Houin G, Boneu B (1992) Influence of molecular weight upon the anticoagulant and pharamcokinetic properties of dermatan sulfate in rabbit. Thromb Res 66: 527–535
Barbanti M, Calanni F, Babbini M, Bergonzini G, Parma B, Marchi E (1993) Antithrombotic activity of Desmin 370. Comparison with a high molecular weight dermatan sulfate. Thromb Res 71: 417–422
Mascellani G, Bianchini P (1990) European patent 1990, No 0221977; USA patent 1990, No 4973580
Barbanti M, Calanni F, Milani RM, Marchi E, Semeraro N, Colucci M (1993) Therapeutic effect of a low molecular weight dermatan sulphate (Desmin 370) in rat venous thrombosis-evidence for an anticoagulant-independent mechanism. Thromb Haemost 69: 147–151
Ofosu FA, Fernandez F, Gauthia D, Buchanan M (1985) Heparin cofactor II and other endogenous factors in the mediation of the antithrombotic and anticoagulant effect of heparin and dermatan sulphate. Semin Thromb Hemostasis 11: 1333–1337
Fernandez F, Van Ryn J, Ofosu FA, Hirsh J, Buchanan MR (1986) The haemorrhagic and antithrombotic effects of dermatan sulphate. Br J Haematol 64: 309–317
Merton RE, Thomas DP (1987) Experimental studies on the relative efficacy of dermatan sulphate and heparin as antithrombotic agents. Thromb Haemost 58: 839–842
Maggi A, Abbadini M, Pagella PG, Borowska A, Pangrazzi J, Donati MB (1987) Antithrombotic properties of dermatan sulphate in a rat venous thrombosis model. Haemostasis 17: 329–335
Van Ryn-McKenna J, Gray E, Weber E, Ofosu FA, Buchanan MR (1989) Effects of sulfated polysaccharides on inhibition of thrombus formation initiated by different stimuli. Thromb Haemost 61: 7–9
Van Ryn McKenna J, Ofosu FA, Gray E, Hirsh J, Buchanan MR (1989) The effects of dermatan sulfate and heparin on inhibition of thrombus growth in vivo. Ann NY Acad Sci 556: 304–312
Ofosu FA, Fernandez F, Anvari N, Caranobe C, Dol F, Cadroy Y, Petitou M, Mardiguian J, Sie P, Boneu B (1988) Further studies on the mechanisms for the antithrombotic effects of polysaccharides in rabbits. Thromb Haemost 60: 188–192
Agnelli G, Cosmi B, Di Filippo P, Ranucci V, Veschi F, Longetti M, Renga C, Barzi F, Gianese F, Lupatelli L, Rinonapoli E, Nenci GG (1992) A randomized, double-blind, placebo-controlled trial of dermatan sulphate for prevention of deep venous thrombosis in hip fracture. Thromb Haemost 67: 203–208
Sie P, Dupouy D, Dol F, Boneu B (1991) Determination of plasma dermatan sulfate at relevant pharmacological concentrations. Semin Thromb Haemost 17: 181–185
Ofosu FA, Modi GJ, Smith LM, Cerskus AL, Hirsh J, Blajchman MA (1984) Heparan sulfate and dermatan sulfate inhibit the generation of thrombin activity in plasma by complementary pathways. Blood 64: 727–747
Ofosu FA, Buchanan MR, Anvari N, Smith LM, Blajchman MA (1989) Plasma anticoagulant mechanisms of heparin, heparan sulfate, and dermatan sulfate. Heparin and Related Polysaccharides. Ann NY Acad Sci 556: 123–131
Thomas DP, Gray E, Merton RE (1990) Potentiation of the antithrombotic action of dermatan sulphate by small amounts of heparin. Thromb Haemost 64: 290–293
Caranobe C, Gabaig AM, Sie P, Boneu B (1991) Antithrombotic effects of the association standard heparin-dermatan sulfate. Thromb Haemost 65:107
Tripodi A, Moia M, Bottasso B, Tenconi PM, Gianese F, Mannucci PM (1991) Effects of subcutaneously administered dermatan sulfate (MF 701) on the coagulation and fibrinolytic parameters of healthy volunteers. Thromb Res 62:663–672
De Rosa V, Legnani C, Maccaferri M, Rodorigo G, Coccheri S (1988) Acute effects of dermatan sulfate on fibrinolysis in healthy volunteers. Fibrinolysis 2 [Suppl 1]: 17
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Legnani, C., Palareti, G., Biagi, R. et al. Acute and chronic effects of a new low molecular weight dermatan sulphate (Desmin 370) on blood coagulation and fibrinolysis in healthy subjects. Eur J Clin Pharmacol 47, 247–252 (1994). https://doi.org/10.1007/BF02570504
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF02570504